Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Assets (2016 - 2025)

ImmunityBio (IBRX) has disclosed Assets for 12 consecutive years, with $501.9 million as the latest value for Q4 2025.

  • Quarterly Assets rose 31.07% to $501.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $501.9 million through Dec 2025, up 31.07% year-over-year, with the annual reading at $501.9 million for FY2025, 31.07% up from the prior year.
  • Assets for Q4 2025 was $501.9 million at ImmunityBio, down from $519.0 million in the prior quarter.
  • The five-year high for Assets was $519.0 million in Q3 2025, with the low at $209.4 million in Q1 2021.
  • Average Assets over 5 years is $372.6 million, with a median of $373.8 million recorded in 2024.
  • The sharpest move saw Assets soared 111.81% in 2021, then dropped 24.19% in 2025.
  • Over 5 years, Assets stood at $468.9 million in 2021, then fell by 22.72% to $362.4 million in 2022, then skyrocketed by 39.21% to $504.5 million in 2023, then dropped by 24.09% to $382.9 million in 2024, then skyrocketed by 31.07% to $501.9 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $501.9 million, $519.0 million, and $402.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.